Pan-immune-inflammation value (PIIV) in Lupus Nephritis PIIV as a predictor of reduced GFR

Main Article Content

Firdevs Ulutaş
Veli Çobankara


Objective: Pan-immune-inflammation value (PIIV) is a newly defined marker that has been validated to predict the prognosis of several oncological diseases. We investigated whether PIIV at diagnosis could predict a reduced glomerular filtration rate (GFR) during follow-up in patients with lupus nephritis (LN).

Material and Methods: We included 45 patients with biopsy-proven LN in this case-control study. PIIV at the diagnosis was calculated for each patient before starting any immunomodulatory and/or immune-suppressive drugs. The study group was classified into two subgroups: patients with a minimum 10 % decreased glomerular filtration rate (GFR) from baseline or preserved GFR. LN-specific indices, inflammation-related laboratory results at diagnosis, medications and developing comorbidities at the follow-up were also noted. Chi-Square Test was used to compare the subgroups. Associated factors were analyzed by logistic regression analysis. Statistically, the significance level was accepted as p˂0.05.

Results: 77.8 % of all patients (n=35) were female, whereas 22.2 % were male. The mean age of the study group was 33.0 ± 13.4 years. The median follow-up period was 36 months (range: 4-108 months). A vast majority of patients (n=32, 71.1%) had class IV LN. GFR reduction was observed in eleven patients (n=11). The mean age at diagnosis, presence of developing hypertension, mean PIIV value, and PIIV >75% were significantly higher in patients with decreased GFR than the patients with preserved GFR (p=0.019, p=0.044, p=0.015, and p=0.011, respectively). In addition, the presence of developing HT and PIIV >75% were found to be statistically significant factors in the multivariate model (p=0.029 and p=0.022).

Conclusion: An increased PIIV at baseline was independently associated with a reduction in GFR in LN patients. A high PIIV might become a new biomarker for the risk of GFR reduction and the need for improved/intensive treatment of these patients.


Download data is not yet available.

Article Details

How to Cite
Ulutaş, F., & Çobankara, V. . (2023). Pan-immune-inflammation value (PIIV) in Lupus Nephritis: PIIV as a predictor of reduced GFR. Medical Science and Discovery, 10(4), 234–238.
Research Article
Received 2023-03-17
Accepted 2023-04-15
Published 2023-04-18


Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022(27);14(11):2675.

Fuca G, Guarini V, Antoniotti C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled analysis of the Valentino and TRIBE first-line trials. Br J Cancer 2020;123:403-9.

Lee LE, Ahn SS, Pyo JY, Song JJ, Park YB, Lee SW. Pan-immune-inflammation value at diagnosis predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2021;39 Suppl 129(2):88-93.

Liu Y, Anders HJ. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin Pract. 2014;128(3-4):224-31.

Rodriguez-Almaraz E, Gutierrez-Solis E, Rabadan E, Rodriguez P, Carmona L, Morales E, et al. Something new about prognostic factors for lupus nephritis? A systematic review. Lupus. 2021;30(14):2256-2267.

Radin M, Miraglia P, Barinotti A, Fenoglio R, Roccatello D, Sciascia S. Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review. Am J Nephrol. 2021;52(7):559-571.

Morales E, Galindo M, Trujillo H, Praga M. Update on Lupus Nephritis: Looking for a New Vision. Nephron. 2021;145(1):1-13.

Caster DJ, Powell DW. Utilization of Biomarkers in Lupus Nephritis. Adv Chronic Kidney Dis. 2019;26(5):351-359.

Bajema IM, Wilhelmus S, Alpers CE, Brujin JA, Colvin RB, Cook HAT, et al. Revision oft he Internaitonal Society of nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018:93(4):789-796.

Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in the assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016;26(3):372-6.

Taha SI, Samaan SF, Ibrahim RA, Moustafa NM, Sehsah EM, Youssef MK. Can Complete Blood Count Picture Tell Us More About the Activity of Rheumatological Diseases? Clin Med Insights Arthritis Musculoskelet Disorders. 2022(22);15:11795441221089182.

Olaru F, Dobel T, Lonsdorf AS, Oehrl S, Maas M, Enk AH, et al. Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis. JCI Insight. 2018(7);3(11):e96492.

Mejia-Vilet JM, López-Hernández YJ, Trujeque-Matos M, Santander-Velez JI, Cano-Verduzco ML, Cruz C, et al. High frequency of nocturnal hypertension in lupus nephritis: should ABPM be implemented in usual practice? Clin Rheumatol. 2020;39(4):1147-1155.

Pogorevici A, Gluhovschi C, Gluhovschi G, Velciov SM, Trandafirescu V, Secrii RV. Hypertension in lupus nephritis. Rom J Intern Med. 2006;44(3):295-316.